유럽. 비소세포암 환자의 1차 치료를 위해 존슨앤존슨의 리브리반트주와 랙라자의 병행요법 승인
https://www.manilatimes.net/2024/12/30/tmt-newswire/globenewswire/european-commission-approves-rybrevant-amivantamab-in-combination-with-lazcluze-lazertinib-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer/2028343
https://www.manilatimes.net/2024/12/30/tmt-newswire/globenewswire/european-commission-approves-rybrevant-amivantamab-in-combination-with-lazcluze-lazertinib-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer/2028343